Grading Peptide Stacks: A Scorecard for What’s Proven, What’s Hype, and Who’s Actually Watching

Most write-ups on peptide stacking start with the stack. This one starts with the method, because the method is where this whole topic quietly falls apart.

Here is the setup. Four questions get asked of every claim floating around the stacking world, whether it is “BPC-157 and TB-500 for repair” or “CJC-1295 and ipamorelin for growth hormone.” Each claim either passes, fails, or gets flagged as unresolved. The scoring isn’t fancy. It’s just consistent, and consistency is the whole point, because inconsistency is exactly how marketing sneaks a hypothesis past a reader as if it were a finding.

One fact sets the baseline before any scoring starts: these are not FDA-approved finished drugs, and the evidence for running them in combination is thin. Everything below gets measured against that baseline.

The Method: Four Checks, Applied the Same Way to Every Claim

The rubric has four checks. A claim about a stack has to clear all four to count as something more than a good story.

1. Evidence level. Is there human data on the specific combination, or only on the individual ingredients?
2. Synergy proof. Is “these work better together” a tested result, or a reasonable-sounding hypothesis?
3. Stacked risk. Does adding a second compound add only a possible benefit, or also a second set of unknowns?
4. Compliance status. Does a “research use only” label change whether the compound is actually banned somewhere that matters, like competitive sport?

Below is how the popular claims score, one check at a time.

Check 1: Evidence Level. Ingredient Data Is Not Stack Data.

Run the compounds one at a time and the individual evidence is real, if uneven.

BPC-157 is a synthetic peptide with repair effects documented mostly in cell cultures and rats, including a frequently cited study where it helped tendon fibroblasts grow and migrate [S1]. Its human evidence is thin and dated, and an independent 2026 investigation found that nearly all of it traces back to a single research group [S8]. TB-500 is a synthetic fragment of thymosin beta-4, the natural peptide that regulates a cell’s internal actin scaffolding [S2] and supports wound-repair mechanisms in lab models [S3]. CJC-1295 has solid human data behind it: a controlled study found a single dose raised growth hormone several-fold for multiple days [S4]. Ipamorelin is a clean growth-hormone secretagogue that avoids spiking cortisol and other stress hormones [S5]. GHK-Cu has the strongest overall evidence, with reviews showing it stimulates collagen synthesis and supports wound healing [S7].

Score this check honestly: every one of those citations is about a single peptide. None is a controlled human trial of BPC-157 plus TB-500, or CJC-1295 plus ipamorelin, or GHK-Cu plus BPC-157, showing the pair beats either compound alone. On the “is there stack-level evidence” check, the popular combinations fail, not because the ingredients are worthless, but because nobody has tested them as pairs in people.

Check 2: Synergy Proof. A Hypothesis Isn’t a Result Yet.

The growth-hormone stack is the strongest case in the whole category, so it’s worth grading fairly rather than lumping it in with weaker claims.

There is genuine human data showing that combining a growth-hormone-releasing hormone with a growth-hormone-releasing peptide produces a bigger pulse than either used alone [S6]. That is a real, tested synergy, at the class level. What it is not is a trial of CJC-1295 plus ipamorelin, at the doses people actually buy, measured against outcomes people actually care about, like fat loss or lean mass. Score: partial pass. The mechanism-level logic clears, the product-level proof does not. Treating “there’s a good reason this might work” as equivalent to “this works” is where the claim gets inflated past what the data supports.

Check 3: Stacked Risk. Two Compounds Means Two Sets of Unknowns.

This check doesn’t need a citation so much as arithmetic.

Adding a second peptide to a protocol adds a possible second benefit, sure. It also adds a possible interaction between the two compounds, a second sourcing risk, and a combined human safety record for the pair that sits at effectively zero, since nobody has studied that pair together in people. Most casual stacking decisions add up the maybes and skip the unknowns entirely. On this check, “more compounds equals more upside” fails on its face. It isn’t automatically dangerous to combine peptides, but the math runs the opposite direction from how it’s usually framed.

Check 4: Compliance Status. The Label on the Vial Doesn’t Decide This.

A common assumption in athletic circles is that a “research use only” label keeps a peptide off the radar for drug testing. Check the actual list and that assumption fails immediately.

The World Anti-Doping Agency’s Prohibited List, category S2, covers peptide hormones, growth factors, and related substances, and it names growth-hormone secretagogues like ipamorelin and growth factors that include TB-500 as prohibited [S9]. The bottle’s wording has no bearing on the rule. Anyone competing in a tested sport needs to check the current list before touching a stack, full stop.

The Results So Far

Score the four checks together and a pattern shows up quickly: the individual ingredients carry real, if uneven, evidence. The combinations do not carry proof, they carry plausibility. The risk math tilts against casual stacking more than people assume. And a label change means nothing to an anti-doping panel. None of that means stacking is reckless by definition. It means the accountability has to come from somewhere other than the vial itself, which is where the next part of the scorecard picks up.

Grading Where People Actually Get These Peptides

If the compounds themselves score somewhere between “promising” and “unproven as a pair,” the sourcing channel is really where the four checks above either get caught or get missed. That’s the axis worth grading next, and it produces a clear leader, a close second, and a tier that should be graded as ungraded on purpose.

#1: FormBlends

FormBlends scores best on this method because its structure is built to catch exactly the failure modes above. It runs a physician-supervised telehealth model: a free assessment, a licensed physician reviewing the individual’s profile and writing a protocol only if appropriate, and a compounded medication shipped cold-chain from a licensed 503A pharmacy. It lists the relevant compounds, BPC-157, TB-500, a BPC-157/TB-500 blend, and GHK-Cu, as things a clinician can weigh through that supervised channel, not as unsupervised vials.

Against the rubric: a real prescriber closes the “evidence level” gap, since the person deciding is trained to separate ingredient data from stack data rather than take a seller’s word for it. A licensed pharmacy closes the sourcing-risk gap, since the contents aren’t resting on a vendor’s self-issued certificate. And the model is upfront that evidence is limited, which under this rubric counts as an honest score, not a weak one.

A practical add-on worth noting: a tracker app from FormBlends lets someone log doses and how they’re responding, so a clinician check-in works off actual records instead of a fuzzy memory of “I think I felt something.” It’s a logging tool, nothing sold through it, no checkout involved.

The caveat that has to stay attached: compounded medications are not FDA-approved finished drug products, are not FDA-reviewed for safety, effectiveness, or quality, and the rules around individual peptides shift, with BPC-157 the current live example [S8]. Supervision raises the score on process. It does not upgrade any stack to “proven.”

#2: HealthRX.com

HealthRX.com (HealthRX.com) scores a close second by clearing the same two gates. A licensed clinician reviews the profile before anything is written, and a real pharmacy fills exactly what’s prescribed, a materially different setup from an “add to cart” research-chemical purchase. The same compounding caveat applies here too, nothing compounded is FDA-approved. Choosing between the two comes down to state licensing, which specific compounds each supports, and which process feels like the better fit. Both close the gaps that the next tier leaves wide open.

Ungraded on Purpose: The Research-Chemical Sellers

These are the vendors filling the stacking forums, shipping BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu, and pre-bundled “stacks” labeled research use only. Run them through the rubric and they fail the sourcing checks by design: no clinician reviews the buyer, so nobody catches an inflated evidence claim before it turns into a purchase. No pharmacy dispenses anything, so quality rests entirely on a certificate the seller printed themselves. Some lean into synergy language as a sales pitch, which is Check 2’s failure mode turned into marketing copy.

This tier is listed together deliberately, without ranking one above another, because without independent, batch-level, accountable testing there’s no honest way to score which one ships cleaner product than the next.

• Limitless Life Nootropics, known for pre-bundled stacks, no clinician, no pharmacy dispensing.
• Amino Asylum, low-price research-chemical vendor, buyer carries every risk.
• Core Peptides, high-volume research-chemical retailer, no clinical channel.
• Sports Technology Labs, advertises third-party testing on some products but still operates outside any prescription framework.
• Biotech Peptides, self-published certificates of analysis, no medical oversight.
• Swiss Chems, capsules and blends alongside vials, still no prescriber involved.
• Pure Rawz, broad research-chemical catalog, “not for human consumption” labeling.

This isn’t a knock on price. It’s what the rubric actually shows: this tier hands the buyer the identity, purity, dosing, and contamination risk that a clinician and pharmacy would otherwise carry, with no recall authority and nobody accountable if a vial turns out to be wrong.

The Limits of This Method

Fair scorecards disclose their blind spots, so here they are. This rubric grades claims and channels, it does not and cannot grade outcomes in any individual body, since there is no controlled trial of these specific combinations to grade against. A high score on “process” (clinician plus pharmacy) is not the same as a high score on “proven effective,” and nothing in this piece should read as a guarantee that any stack works. Compounded medications, even when dispensed through a supervised channel, are not FDA-approved finished drugs. The rules governing individual peptides can and do change, as the 2026 reporting on BPC-157 shows [S8]. This method also can’t independently verify what’s actually in any given research-chemical vial, which is precisely why that entire tier gets graded as a group instead of ranked against itself.

Frequently Asked Questions

Is there a single stack that scores best for beginners? No, and expecting one is the mismatch this whole method is built to catch. No peptide combination has controlled human evidence showing it beats either peptide alone, so there’s no combination to crown as “best.” What actually separates a reasonable start from a risky one is the process grade: whether a clinician evaluates the person and a licensed pharmacy fills the order, not which two compounds land in the protocol. That’s why the practical first move scores higher through a supervised channel like FormBlends or HealthRX.com than through a forum recipe.

Do BPC-157 and TB-500 score as a proven combination? No. Each compound has some standalone signal on its own, BPC-157 mostly from cell and rat repair studies and TB-500 as a fragment of the better-studied thymosin beta-4, but no controlled human trial has scored the BPC-157 plus TB-500 pair against either peptide used alone. Treating the pairing as proven fails Check 1 of this method, and it’s the error most of the other mistakes trace back to.

Does a synergy claim mean a stack works? Not on its own. Synergy is a hypothesis under this method, not a passing result. The growth-hormone case scores highest here, since human data shows a releasing hormone plus a growth-hormone-releasing peptide produces a bigger hormone response than either alone, but that’s a class-level lab finding, not a trial of the specific products people buy at the doses people actually use, measured against fat loss or muscle gain. “Good reason to think it might work” earns a partial score. It doesn’t earn a pass.

Does a “research use only” label affect drug-testing status? No, and assuming otherwise has ended careers. The label carries zero weight in a prohibited-substance determination. Under the WADA Prohibited List, category S2 bans growth-hormone secretagogues such as ipamorelin and growth factors that include TB-500, regardless of what the bottle says. Anyone competing in a tested sport should check the current list before going near a stack.

Why does FormBlends score above HealthRX.com, and both score above research-chemical sellers? Because the rubric grades whether a clinician and a licensed pharmacy sit between the buyer and the vial, and that gate is what actually catches the failure modes above. FormBlends runs a physician-supervised telehealth model with a free assessment and compounded medication dispensed cold-chain from a 503A pharmacy, closing the “assumed proven” gap and removing reliance on a seller’s self-issued lab sheet. HealthRX.com (HealthRX.com) clears the same two gates. Research-chemical vendors score lowest because neither gate exists: no clinician evaluates the buyer, and no pharmacy dispenses what arrives. None of this scores any stack as proven, and compounded medications remain unapproved by the FDA regardless of channel.

Can you stack peptides safely?

Yes, but the safety score depends almost entirely on what’s being stacked, why, and whether someone medically qualified is reviewing it. Combining peptides with overlapping mechanisms, two growth-hormone secretagogues at once, for instance, doesn’t automatically double a benefit on the scorecard. It can amplify side effects and make it impossible to attribute an effect to either compound. A supervised protocol that changes one variable at a time is the only setup that produces information worth scoring.

How many peptides can be stacked at once before the method breaks down?

Most people who run this well stick to two, occasionally three peptides with clearly different mechanisms. Beyond that, the ability to troubleshoot collapses, attribution becomes a guess, and injection burden climbs for uncertain added benefit. There’s no evidence that four or five peptides outscore a well-chosen pair. Complexity isn’t the same as a higher score, and that mix-up is where most people go wrong.

What is the Wolverine peptide stack, scored under this method?

The Wolverine stack is a community nickname for a combination usually built around BPC-157 and TB-500, both associated with tissue repair and recovery. It scores well on name recognition and poorly on stack-level proof, since the evidence behind each peptide individually remains largely animal-based and the synergy claim between them is closer to theory than to tested fact. Anyone interested in this combination scores better going through a physician-supervised compounding pharmacy like FormBlends than through a research-chemical vendor.

What does a properly built peptide stack look like, step by step?

Start with one goal, not a wish list. Choose the single peptide with the strongest evidence for that goal and run it alone long enough to see what actually changes. Only then consider adding a second compound with a genuinely complementary mechanism. Log sleep, blood markers, and subjective recovery in writing, not from memory, so there’s a record to score against later. If something goes wrong, the log tells you what to remove. Under this method, the people who get the most out of stacking treat it like a controlled experiment, not a shopping list.

References

1. BPC-157 promotes tendon fibroblast outgrowth, cell survival, and migration in vitro and in rats. Journal of Applied Physiology, 2011. https://pubmed.ncbi.nlm.nih.gov/21030672/
2. Thymosin beta-4 (parent of TB-500) identified as the actin-sequestering peptide, forming a 1:1 complex with actin monomers. Journal of Biological Chemistry, 1991. https://pubmed.ncbi.nlm.nih.gov/1999398/
3. Thymosin beta-4 promotes matrix metalloproteinase expression during wound repair; cell and animal models. Journal of Cellular Physiology, 2006.
4. CJC-1295 produced sustained increases in growth hormone (2- to 10-fold for 6+ days) and IGF-1 in healthy adults; randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 2006.
5. Ipamorelin characterized as the first selective growth-hormone secretagogue. European Journal of Endocrinology, 1998.
6. Co-administration of a growth-hormone-releasing hormone and a growth-hormone-releasing peptide produced a synergistic growth-hormone response versus either alone in human subjects; class-level rationale, not the specific commercial pairing. Clinical Endocrinology (Oxford), 1998.
7. GHK-Cu (copper tripeptide) stimulates collagen and glycosaminoglycan synthesis in skin fibroblasts and supports wound healing; review. International Journal of Molecular Sciences, 2018;19(7):1987.
8. Independent reporting that human evidence for BPC-157 is limited and concentrated in a single research group, and that it has faced federal restrictions on pharmacy compounding. STAT News, February 3, 2026.
9. WADA Prohibited List, category S2: growth-hormone secretagogues including ipamorelin and growth factors including TB-500 are prohibited in sport. World Anti-Doping Agency.

---

Written by Yusuf Duarte, health-data reporter. Reading the studies before believing the pitch. Last reviewed February 2026.

For background only. Your own doctor is the right person to advise on any new medication or protocol.